Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Pipeline of Psoriasis Market Covering 140 Companies Reviewed for H1 2016


News provided by

RnR Market Research

13 May, 2016, 10:00 GMT

Share this article

Share toX

Share this article

Share toX

PUNE, India, May 13, 2016 /PRNewswire/ --

RnRMarketResearch.com adds "Psoriasis - Pipeline Review, H1 2016" market research report that provides an overview of the Psoriasis's therapeutic pipeline with comprehensive information and comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Psoriasis with 216 market data tables and 17 figures, spread across 771 pages is available at http://www.rnrmarketresearch.com/psoriasis-pipeline-review-h1-2016-market-report.html .

The report also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Psoriasis Pipeline Review, H1 2016 report include 3SBio Inc., 4SC AG, Abeome Corporation, AbGenomics International, Inc., ADC Therapeutics Sarl, Addex Therapeutics Ltd, Advinus Therapeutics Ltd., Affibody AB, Ajinomoto Pharmaceuticals Co., Ltd., AlbireoPharma, Almirall, S.A., Amgen Inc., Anacor Pharmaceuticals, Inc., AnaptysBio, Inc., ApoPharma Inc., Arena Pharmaceuticals, Inc., Argos Therapeutics, Inc., Arrien Pharmaceuticals, LLC, AstraZeneca Plc, Athenex, Inc., Aurigene Discovery Technologies Limited, Avexxin AS, BIOCAD, Biocon Limited, BioLingus AG, BioMAS Ltd., Biomics Biotechnologies Co., Ltd., Bionomics Limited, Bionovis SA, Boehringer Ingelheim GmbH, Brickell Biotech, Inc., Bristol-Myers Squibb Company, C4X Discovery Holdings PLC, Can-Fite BioPharma Ltd., Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., ChemoCentryx, Inc., Chipscreen Biosciences Ltd, ChironWells GmbH, Coherus BioSciences, Inc., Compugen Ltd., Convoy Therapeutics, Inc., Creabilis SA, Crescendo Biologics Limited, Curapel Limited, Delenex Therapeutics AG, Domainex Limited, Dr. August Wolff GmbH & Co. KG Arzneimittle, Effimune SAS, Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Exicure, Inc., Foamix Pharmaceuticals Ltd., Forward Pharma A/S, Galectin Therapeutics, Inc., Gem Pharmaceuticals, LLC, Gene Signal International SA, Genentech, Inc., Genor BioPharma Co., Ltd., GlaxoSmithKline Plc, GliaCure Inc., GlycoMar Limited, Grupo Ferrer Internacional, S.A., Hydra Biosciences, Inc., Idera Pharmaceuticals, Inc., Immune Pharmaceuticals Inc., Immune Response BioPharma, Inc., Immungenetics AG, Innovent Biologics, Inc., Invion Limited, Jenrin Discovery, Inc., Johnson & Johnson, Kadmon Corporation, LLC, KaloBios Pharmaceuticals, Inc., Kineta, Inc., Kyowa Hakko Kirin Co., Ltd., Lead Pharma Holding B.V., Lee's Pharmaceutical Holdings Limited, LEO Pharma A/S, Lipidor AB, Lupin Limited, Mabion SA, mAbxience S.A., Maruho Co., Ltd., MediGene AG, Merck KGaA, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., Neovacs SA, Nimbus Therapeutics, LLC, NovaLead Pharma Pvt. Ltd., Novan, Inc., Novartis AG, Nuevolution AB, Oncobiologics, Inc., Panacea Biotec Limited, Pfizer Inc., Pharis Biotec GmbH, Pharmedartis GmbH, Phenex Pharmaceuticals AG, PinCell srl, Polichem S.A., Promius Pharma, LLC, Protalix BioTherapeutics, Inc., Prothena Corporation Plc, Provectus Biopharmaceuticals, Inc., RedHill Biopharma Ltd., Rigel Pharmaceuticals, Inc., Sandoz International GmbH, Sareum Holdings Plc, Selvita S.A., Shanghai Celgen Bio-Pharmaceutical Co., Ltd., Shulov Innovative Science Ltd., Sigmoid Pharma Limited, SignPath Pharma Inc, Soligenix, Inc., Spherium Biomed S.L., Stemline Therapeutics, Inc., sterna biologicals Gmbh & Co KG, Sucampo Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Ltd., SWITCH Biotech LLC, Syntrix Biosystems, Inc., Takeda Pharmaceutical Company Limited, Tasly Pharmaceutical Group Co., Ltd., Telormedix SA, TetraLogic Pharmaceuticals, Teva Pharmaceutical , Industries Ltd., Therapeutic Proteins International, LLC, Therapix Biosciences Ltd, Tolero Pharmaceuticals, Inc., UCB S.A., Valeant Pharmaceuticals International, Inc., Vitae Pharmaceuticals, Inc., vTv Therapeutics LLC, Wellstat Therapeutics Corporation, Yuhan Corporation and Ziarco Pharma Ltd.

Order a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=542535 .

Another newly published market research report titled on Actinic (Solar) Keratosis - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Actinic (Solar) Keratosis Pipeline market research report of 95 pages is available at http://www.rnrmarketresearch.com/actinic-solar-keratosis-pipeline-review-h1-2016-market-report.html .

Explore more reports on Dermatology therapeutics.

About Us:   

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us:

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
sales@rnrmarketresearch.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.